Z
Zhou Hairong
Researcher at University of Auckland
Publications - 11
Citations - 1654
Zhou Hairong is an academic researcher from University of Auckland. The author has contributed to research in topics: Tyrosine kinase & Quinazoline. The author has an hindex of 8, co-authored 11 publications receiving 1631 citations.
Papers
More filters
Patent
Irreversible inhibitors of tyrosine kinases
Alexander James Bridges,William Alexander Denny,Ellen Myra Dobrusin,Annette Marian Doherty,David W. Fry,Dennis Joseph Mcnamara,Howard Daniel Hollis Showalter,Jeffrey Bruce Smaill,Zhou Hairong +8 more
TL;DR: In this article, a method for treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis and a pharmaceutical composition that comprises a compound that is an irreversible inhibitor of tyrosine kinases.
Journal ArticleDOI
Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor
Alexander James Bridges,Zhou Hairong,Donna Reynolds Cody,Gordon W. Rewcastle,Amy McMichael,H. D. Hollis Showalter,David W. Fry,and Alan J. Kraker,William A. Denny +8 more
TL;DR: It is proposed that certain substituted analogues possess the ability to induce a change in the conformation of the receptor when they bind, and there is some bulk tolerance for substitution in the 6- and 7-positions of the quinazoline, so that 32 is not the optimal inhibitor for the induced conformation.
Journal ArticleDOI
Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.
Gordon W. Rewcastle,William A. Denny,Alexander James Bridges,Zhou Hairong,Donna Reynolds Cody,Amy McMichael,David W. Fry +6 more
TL;DR: A series of 4-substituted quinazolines and related compounds prepared and evaluated for their ability to inhibit the tyrosine kinase activity of the epidermal growth factor receptor on a phospholipase C-gamma 1-derived substrate shows a narrow structure-activity relationship (SAR) for the basic ring system.
Journal ArticleDOI
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Jeffrey Bruce Smaill,Brian D. Palmer,Gordon W. Rewcastle,William A. Denny,Dennis J. McNamara,Ellen M. Dobrusin,Alexander James Bridges,Zhou Hairong,H. D. H. Showalter,R. T. Winters,W. R. Leopold,David W. Fry,James M. Nelson,V. Slintak,W. L. Elliot,Bill J. Roberts,Patrick W. Vincent,S. J. Patmore +17 more
TL;DR: A series of 6- and 7-acrylamide derivatives of the 4-(phenylamino)quinazoline and -pyridopyrimidine classes of epidermal growth factor receptor (EGFR) inhibitors showed significant tumor growth inhibition (stasis) over a dose range, and the poor aqueous solubility of the compounds was a drawback.
Journal ArticleDOI
Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
Gordon W. Rewcastle,Brian D. Palmer,Andrew M. Thompson,Alexander James Bridges,Donna Reynolds Cody,Zhou Hairong,David W. Fry,and Amy McMichael,William A. Denny +8 more
TL;DR: Select compounds were evaluated for their ability to inhibit EGFR autophosphorylation in A431 cells, and a positive quantitative correlation was found between this activity and inhibitory activity against the isolated enzyme.